Fortrea Holdings (FTRE) Shares Outstanding (Weighted Average) (2022 - 2026)
Fortrea Holdings (FTRE) reported Shares Outstanding (Weighted Average) of $93.6 million for Q1 2026, up 3.88% on a YoY basis from $90.1 million in Q1 2025, and up 3.54% quarter-over-quarter from $90.4 million in Q2 2025.
Fortrea Holdings (FTRE) Shares Outstanding (Weighted Average) (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Shares Outstanding (Weighted Average) for 5 years, with the latest figure at $93.6 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 3.88% year-over-year to $93.6 million; the trailing twelve-month figure through Mar 2026 stood at $93.6 million (up 3.88% YoY), and the FY2024 full-year result was $89.5 million, up 0.79% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $93.6 million, up from $90.4 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $93.6 million in Q1 2026, with the low at $88.8 million in Q2 2022.
- Historically, Shares Outstanding (Weighted Average) has averaged $89.5 million across 5 years, with a median of $89.0 million in 2022.
- Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) changed 0.0% — and 2026, when it advanced 3.88%.
- Fortrea Holdings' Shares Outstanding (Weighted Average) stood at $88.8 million in 2022, then changed by 0.0% to $88.8 million in 2023, then climbed by 0.79% to $89.5 million in 2024, then climbed by 1.01% to $90.4 million in 2025, then increased by 3.54% to $93.6 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $93.6 million (Q1 2026), $90.4 million (Q2 2025), and $90.1 million (Q1 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn | 93.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93.60 Mn |
| Jun 30, 2025 | 90.40 Mn |
| Mar 31, 2025 | 90.10 Mn |
| Dec 31, 2024 | 89.50 Mn |
| Sep 30, 2024 | 89.40 Mn |
| Jun 30, 2024 | 89.30 Mn |
| Mar 31, 2024 | 89.20 Mn |
| Dec 31, 2023 | 88.80 Mn |
| Sep 30, 2023 | 88.80 Mn |
| Jun 30, 2023 | 88.80 Mn |
| Mar 31, 2023 | 88.80 Mn |
| Dec 31, 2022 | 88.80 Mn |
| Sep 30, 2022 | 88.80 Mn |
| Jun 30, 2022 | 88.80 Mn |